Complimentary Commercial Content
The availability of an effective, non-NSAID monthly treatment for canine osteoarthritis pain is an exciting advance for everyone who cares about improving quality of life for dogs, owners and veterinary professionals, writes Kristen Green Seymour. She provides perspective on the significance of the approval Zoetis received for Librela™ (bedinvetmab injection).
Sources:
- AAHA NEWStat, May 10, 2023. Link.
- Zoetis, May 5, 2023. Link. Company press release. Product page <Link>. Also see professional marketing site (video) <Link>.
Librela is a monoclonal antibody therapy administered in the clinic that targets nerve growth factor to control canine OA pain. It is to be administered by sub-cutaneous injection by a veterinary professional to dogs over one year of age.
INSIGHTS: AHD requested more information on the monthly, sub-Q dosing. Zoetis explained the total volume for Librela injections will be 1 ML or 2 ML, depending on a dog’s body weight. Veterinarians should use their own discretion for the most appropriate injection site as there was no specified site for injection in the clinical studies.